Evgen Pharma recruits over 100 patients into COVID-19 trial
Study is investigating company’s lead asset SFX-01
Read More
Tag: Evgen Pharma
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
